- Home
- NUWE vs GCTK Comparison
NUWE vs GCTK Comparison
Compare NUWE & GCTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NUWE | GCTK |
|---|---|---|
| Founded | 1999 | 2001 |
| Country | United States | United States |
| Employees | 38 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 1.4M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | NUWE | GCTK |
|---|---|---|
| Price | $1.14 | $0.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 31.1K | ★ 3.8M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 31.22 |
| Revenue | N/A | ★ $589,462.00 |
| Revenue This Year | $11.14 | N/A |
| Revenue Next Year | $18.51 | N/A |
| P/E Ratio | ★ N/A | $0.03 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.19 | $0.09 |
| 52 Week High | $25.95 | $15.90 |
Technical Indicators
Market Signals| Indicator | NUWE | GCTK |
|---|---|---|
| Relative Strength Index (RSI) | 42.11 | 44.93 |
| Support Level | $0.96 | $0.64 |
| Resistance Level | $1.19 | $1.02 |
| Average True Range (ATR) | 0.07 | 0.13 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 11.60 | 23.08 |
Price Performance
Historical ComparisonAbout NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About GCTK GlucoTrack Inc.
GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.